Arthneeti
Latest: Alivus Life Q2 FY27 (Jul–Sep 2026) results →This page is Q1 FY27 (Apr–Jun 2026).All Q1 FY27 results →
AL

Alivus Life

Q1 FY27Pharmaceuticals & Biotechnology

Alivus Life Q1 FY27 earnings call: Revenue & Margins

Q1 FY27 earnings call: what management said on revenue, margins and capex.

Price₹1,348
Market cap₹16.6K Cr
P/E26.7
Updated25 Aug 2026
Read4 min read

What the Q1 FY27 call signalled

3 of 4 strong

RevenueModerate growth
MarginMargins slightly up
CapexCapex planned
Order bookOrder book rising

The short version

Alivus Life Sciences expects revenue growth of 10% to 12% in FY '27, with stronger growth skewed towards the second half of the year. Revenue Growth: Alivus is guiding for 10% to 12% revenue growth in FY '27, with growth skewed towards the second half of the year.

From Alivus Life's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.

Revenue & Sales Performance

Moderate growth
  • Alivus Life Sciences expects revenue growth of 10% to 12% in FY '27, with stronger growth skewed towards the second half of the year.
  • Non-GPL business is driving strong growth, with a 26.5% year-on-year increase in Q1 FY '27, supported by a robust product pipeline and recent launches.
  • CDMO business is anticipated to accelerate in H2 FY '27 and beyond as new projects commercialize, contributing to faster growth than the overall business.
  • The company is working on 7 active CDMO projects and anticipates closing 2 new CDMO contracts in early H2 FY '27.
  • Pipeline of 28-29 new high-potent API products being commercialized gradually, with significant launches expected from FY '28 onward.

2 more points from Alivus Life's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Alivus Life said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Capex planned
  • Capex for Q1 FY '27 was INR85 crores; expected capex for FY '27 is approximately INR540 crores.
  • Priority capex focus remains on completion of expansions at Dahej (160KL increase) and Ankleshwar (110KL increase), both on track.
  • Solapur Phase 1 and 1.1 nearing completion, to be operational by Q3 FY '27, with inspections planned within a year post-operation for regulatory approvals.
  • Solapur expansion (Phase 3) has been delayed by about a year to avoid under-absorption and is planned as a greenfield project.
  • New R&D center construction at Taloja has begun and is progressing on schedule.
  • Investment focus on new API launches and improving manufacturing capabilities, especially for regulated markets.

2 more points from Alivus Life's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
1KRM Ayurveda
Rev 1Mar 1
2Accretion Pha.
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Alivus Life said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

Order book rising
  • Alivus Life Sciences is actively engaged in about 7 ongoing CDMO projects.
  • Revenue currently comes from 5 existing projects.
  • There are new inquiries beyond these 7 projects, indicating a steady flow of potential business.
  • The CDMO segment is expected to accelerate growth in H2 FY '27 and continue expanding in FY '28 with new projects kicking in.
  • The company is confident of maintaining steady demand and growth from its existing pipeline and new launches.
  • The robust product pipeline includes 29 active high-potent API products with a total addressable market of $82 billion.

2 more points from Alivus Life's call on order book

Create a free account to keep reading this call

Alivus Life — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹682 Cr, net profit ₹197 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Alivus Life Sciences Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • KRM Ayurveda (Q1 FY27)

    Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r

  • Balaxi Pharma (Q1 FY27)

    Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr

  • Sanjiv.Parant. (Q1 FY27)

    Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani

  • Natural Capsules (Q1 FY27)

    Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharma.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Alivus Life and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Alivus Life Q1 FY27 results?

Alivus Life Sciences expects revenue growth of 10% to 12% in FY '27, with stronger growth skewed towards the second half of the year. Revenue Growth: Alivus is guiding for 10% to 12% revenue growth in FY '27, with growth skewed towards the second half of the year.

What is Alivus Life share price analysis?

Alivus Life currently shows a below-average growth signal. The stock trades at a P/E of 26.7 with a market cap of ₹16,585 Cr. Investors should review the full earnings analysis for detailed insights.

Is Alivus Life planning capital expenditure?

Capex for Q1 FY '27 was INR85 crores; expected capex for FY '27 is approximately INR540 crores.

Keep Alivus Life on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.